Outlook Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.91 | -$0.91 | -$0.91 |
| Q2 2024 | 0 | -$1.03 | -$1.03 | -$1.03 |
| Q3 2024 | 3 | -$0.86 | -$0.73 | -$0.81 |
| Q4 2024 | 0 | -$0.95 | -$0.95 | -$0.95 |
| Q1 2025 | 2 | -$0.77 | -$0.77 | -$0.77 |
| Q2 2025 | 2 | -$0.60 | -$0.60 | -$0.60 |
| Q3 2025 | 2 | -$0.46 | -$0.46 | -$0.46 |
Outlook Therapeutics, Inc. Earnings Date And Information
Outlook Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.83 earnings per share for the quarter, topping analysts' consensus estimates of $-1.06 by $0.23. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Outlook Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-4.72 diluted earnings per share) and currently has a price-to-earnings ratio of -1.84. Outlook Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 19th, 2024 based on prior year's report dates.
Outlook Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/14/2024 | Q3 2024 | -$1.06 | $1.91 | 2.97 | $0 | $0 |
| 05/15/2024 | Q2 2024 | -$0.88 | -$8.01 | -7.13 | $0 | $0 |
| 02/14/2024 | Q1 2024 | -$1.00 | -$0.86 | 0.14 | $7.75 M | $0 |
| 01/24/2024 | Q4 2023 | -$1.00 | $2.49 M | $0 | ||
| 08/14/2023 | Q3 2023 | -$0.80 | -$1.61 | -0.81 | $0 | |
| 05/15/2023 | Q2 2023 | -$1.20 | -$0.52 | 0.68 | $0 | |
| 02/14/2023 | Q1 2023 | -$0.80 | -$1.90 | -1.1 | $0 | |
| 01/24/2023 | Q4 2022 | -$1.35 | $0 | |||
| 08/10/2022 | Q3 2022 | -$1.60 | -$1.59 | 0.01 | $0 | |
| 05/13/2022 | Q2 2022 | -$1.40 | -$1.80 | -0.4 | $0 | |
| 02/14/2022 | Q1 2022 | -$1.40 | -$1.54 | -0.14 | $0 | |
| 12/23/2021 | Q4 2021 | -$1.59 | $300,000 | $0 | ||
| 08/13/2021 | Q3 2021 | -$1.60 | -$1.45 | 0.15 | $325,000 | $0 |
| 05/14/2021 | Q2 2021 | -$2.20 | -$1.74 | 0.46 | $0 | |
| 02/16/2021 | Q1 2021 | -$0.08 | -$2.37 | -2.29 | $220,000 | $0 |
| 12/23/2020 | Q4 2020 | -$0.08 | -$2.19 | -2.11 | $162,500 | $0 |
| 08/14/2020 | Q3 2020 | -$1.20 | -$0.66 | 0.54 | $216,667 | $0 |
| 05/15/2020 | Q2 2020 | -$2.00 | -$2.38 | -0.38 | $0 | |
| 02/14/2020 | Q1 2020 | -$0.25 | -$11.11 | -10.86 | $333,333 | $0 |
| 12/19/2019 | Q4 2019 | -$5.60 | -$7.06 | -1.46 | $637,500 | $5.85 M |
Outlook Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Outlook Therapeutics, Inc.'s earnings date?
Outlook Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 19th, 2024 based off last year's report dates.
-
Did Outlook Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Outlook Therapeutics, Inc. (:OTLK) reported $-0.83 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.06 by $0.23.
-
How can I listen to Outlook Therapeutics, Inc.'s earnings conference call?
The conference call for Outlook Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Outlook Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Outlook Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Outlook Therapeutics, Inc. generate each year?
Outlook Therapeutics, Inc. (:OTLK) has a recorded net income of $0. Outlook Therapeutics, Inc. has generated $-4.72 earnings per share over the last four quarters.
-
What is Outlook Therapeutics, Inc.'s price-to-earnings ratio?
Outlook Therapeutics, Inc. (:OTLK) has a price-to-earnings ratio of -1.84 and price/earnings-to-growth ratio is -0.08.
